The effect of daily administration of prasterone ( @ , @ mg , @ mg or @mg ) for @ weeks on FSD in @ postmenopausal women with or without MSD at baseline was evaluated in a prospective , randomized , double-blind , and placebo-controlled phase III clinical trial .